Tevogen.ai builds alpha version of predictcell™ model with microsoft and databricks; observes drastic time reduction in target analysis translating to potential savings of billions in drug development costs

Warren, n.j., july 14, 2025 (globe newswire) --  tevogen (“tevogen bio holdings inc.” or “company”) (nasdaq: tvgn) today announced that its artificial intelligence initiative, tevogen.ai, in collaboration with microsoft (nasdaq: msft) and databricks, has successfully built the alpha version of its foundational predictcell™ model.
MSFT Ratings Summary
MSFT Quant Ranking